We are committed to extending and enhancing the lives of people living with blood cancers.

Myelodysplastic syndromes (MDS) are a group of blood cancers caused by disruption of normal hematopoiesis in the bone marrow, where not enough healthy blood cells are made, and are characterized by cytopenias (such as anemia), risk of progression to acute myeloid leukemia (AML), and mortality.

Lower-risk myelodysplastic syndromes (LR-MDS) is a blood cancer that often progresses to require increasingly intensified management of key symptoms such as anemia and resulting fatigue. These symptomatic LR-MDS patients frequently become red blood cell transfusion dependent, which has been shown to be associated with short- and long-term clinical consequences that reduce quality of life and shorten survival. There is a high unmet need for many LR-MDS patients, particularly those with characteristics having poorer prognosis.

Patients with MF are typically treated with Janus-associated kinase inhibitors (JAKis). Unfortunately, the majority of patients become unresponsive to JAKis within five years, resulting in very poor overall survival prognosis. These patients have high unmet need for treatments  that can extend survival.

The current treatment approach for AML consists of chemotherapy (anthracycline plus cytarabine), an approach that has been largely unchanged for more than 40 years, or chemotherapy plus a targeted therapy against specific mutations. Despite initial response to these treatments, the majority of AML patients will suffer a relapse, at which point the condition is incurable with standard therapy. New treatments that can improve outcomes after chemotherapy are critical to extending and enhancing the lives of patients with AML.